Aytu BioPharma, Inc.
AYTU · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $31 | $20 | $23 | $19 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $31 | $24 | $29 | $22 |
| Inventory | $11 | $12 | $12 | $11 |
| Other Curr. Assets | $6 | $6 | $9 | $8 |
| Total Curr. Assets | $79 | $62 | $73 | $60 |
| Property Plant & Equip (Net) | $2 | $2 | $4 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $42 | $52 | $59 | $71 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $1 | $1 | $0 |
| Other NC Assets | $1 | $2 | $1 | $1 |
| Total NC Assets | $45 | $57 | $65 | $78 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $124 | $119 | $138 | $138 |
| Liabilities | – | – | – | – |
| Payables | $11 | $10 | $13 | $11 |
| Short-Term Debt | $11 | $5 | $9 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $41 | $47 | $47 | $50 |
| Total Curr. Liab. | $63 | $62 | $69 | $64 |
| LT Debt | $12 | $11 | $22 | $14 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $1 | $1 | $0 |
| Other NC Liab. | $30 | $17 | $6 | $15 |
| Total NC Liab. | $42 | $29 | $29 | $29 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $1 | $0 |
| Total Liabilities | $105 | $91 | $98 | $93 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$334 | -$320 | -$304 | -$287 |
| AOCI | $0 | $0 | $0 | -$0 |
| Other Equity | $353 | $348 | $343 | $331 |
| Total Equity | $19 | $28 | $39 | $44 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $124 | $119 | $138 | $138 |
| Net Debt | -$8 | -$4 | $7 | -$1 |